Newsletter

Today on In-PharmaTechnologist.com

	Bill could cripple FDA and harm patients; PhRMA
	Driam launches cycled continuous tablet coating system
	Pfizer and GSK may feel impact of Wyeth vs. Levine ruling
	Genzyme accused of cGMP deficiencies by FDA
	Obama overturns stem cell research funding ban
	Roche and Genentech reach agreement on $47bn deal

Related Industry News

	Penn Pharma expands in Wales
	PDII losses mount in "very disappointing" '08
	ACM binds Pivotal into the central laboratory fold
	JLL starts Patheon acquisition bid

Breaking News on Pharmaceutical Technology

In association with

Daily 12-Mar-2009

ACCESS FULL STORIES

Bill could cripple FDA and harm patients; PhRMA

The backlash against the re-importation bill has begun, with PhRMA warning that the legislation could cripple the FDA's ability to protect patients and open the door to counterfeits... Read

Driam launches cycled continuous tablet coating system

German coating technology specialist Driam hopes its new Driaconti-T continuous tablet coating platform will win over manufacturers wishing to improve process efficiency in times of economic gloom... Read

Pfizer and GSK may feel impact of Wyeth vs. Levine ruling

Drug giants Pfizer and GSK may be among the first affected by last week's US Supreme Court ruling upholding a product liability lawsuit against Wyeth despite FDA approved labelling... Read

Genzyme accused of cGMP deficiencies by FDA

The FDA has found "significant objectionable conditions" at the Genzyme manufacturing facility that makes Lumizyme, creating another issue in the product's approval process... Read

Obama overturns stem cell research funding ban

The US green light for federally funded embryonic stem cell research is being hailed as a victory by the US drug industry, which predicts it will open the flood gates for novel medications and help revitalise the sector... Read

Roche and Genentech reach agreement on $47bn deal

After eight months of negotiations Roche and Genentech have reached an agreement, with the Swiss pharma buying out the US biotech for $46.8bn (€36.6bn)... Read

All News Headlines for: March | February | January



		SPONSORED LINK Finefoods: A Solidity Of A Vision Finefoods. The experience and the know-how to develop the best possible product. The passion and the rigour of a team of specialists. The solidity of the flexible vision in each process. The reliability of a strong team always available to assist you. FINEFOODS Nutraceutical and Pharmaceutical Contract Manufacturing... Click Here

RELATED INDUSTRY NEWS

Penn Pharma expands in Wales

At a time when many companies are downsizing, UK-based contract manufacturer Penn Pharmaceuticals has just announced a £12m (€13.5m) redevelopment project that could see the creation of 133 new jobs... Read

PDII losses mount in "very disappointing" '08

The slashing of pharma's in-house teams did not help contract sales provider PDII in 2008, with the company recording an operating loss of $36.4m (€28.5m), compared with a $14.3m deficit the previous year... Read

ACM binds Pivotal into the central laboratory fold

US contract research organisation ACM Global Central Laboratory has bought its longstanding business partner Pivotal Laboratories of the UK in a bid to boost its international reach... Read

JLL starts Patheon acquisition bid

Private equity firm JLL Patheon Holdings went ahead yesterday with its unsolicited $2-per-share bid for Patheon that would take the company into private ownership... Read

PREVIOUS HEADLINES

Re-importation bill would punish big pharma's actions; Dorgan

Following the proposal of his bill re-importation bill Senator Byron Dorgan has accused some of big pharma of taking actions that would be illegal under the Act and outlined the punishments they could face... Read

MannKind picks up the pieces of Pfizer's failure

MannKind is trying to buy a Pfizer insulin facility for $33m (€26m) as it continues to push Afresa towards commercialisation but, like many things in the saga, the deal might not be straightforward... Read

Merck moves for Schering in $41bn mega-merger

The year of the mega-merger continues with Merck & Co's move to buy Schering-Plough for $41.1bn, with the intention of boosting its pipeline, entering new markets and creating a "powerful biologics presence"... Read

AMPAC site boosts continuous process capacity

AMPAC Fine Chemicals has inaugurated its kilogram scale current good manufacturing practice (cGMP) compliant facility, which can handle batch or continuous processing... Read

	TECHNICAL / WHITE PAPERS, CASE STUDIES, WEB CASTS
Strategic and Tactical Benefits of Automated Sample Preparation in Pharmaceutical Development and Quality Labs - Technical / white paper Generate sales leads with a good white paper - Technical / white paper The Importance of Regular In-Lab Checking of Pipettes - Technical / white paper Discover new ways to improve ODT performance with Fuji F-MELT® system - Technical / white paper

Free Newsletters for Pharmaceuticals & Science
Choose from over 20 industry e-newsletters

Free e-mail alerts
Please indicate your area of interest and receive free alerts directly to your inbox
Product Categories
Cleanroom, safety equipment, supplies Contract services (outsourcing) Drug delivery systems Ingredients, excipients and raw materials IT solutions	Lab equipment & consumables Packaging machinery & supplies Processing (automation, control, separation) QA/QC & validation Tabletting, coating & ancillary equipment

To continue to receive this newsletter in your inbox, please add
newsletter@in-pharmatechnologist.com to your address book